Alisol A Inhibited the Proliferation, Migration, and Invasion of Nasopharyngeal Carcinoma Cells by Inhibiting the Hippo Signaling Pathway.


Journal

Yonsei medical journal
ISSN: 1976-2437
Titre abrégé: Yonsei Med J
Pays: Korea (South)
ID NLM: 0414003

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 18 03 2021
revised: 07 07 2021
accepted: 13 07 2021
entrez: 24 9 2021
pubmed: 25 9 2021
medline: 28 9 2021
Statut: ppublish

Résumé

Alisol A is a bioactive triterpenoid isolated from the Rhizoma Alismatis. Previous studies have shown that alisol A has anticancer potential. In this study, we explored the effect of alisol A on the growth of nasopharyngeal carcinoma (NPC) cells. MTT assay, colony formation assay, flow cytometry, transwell assay, wound healing assay, and western blotting were used to assess cell viability, proliferation, cell cycle, migration, invasion, and protein expression, respectively, in vitro. AutoDock Vina and Discovery Studio software were used for molecular docking. Alisol A inhibited the viability, proliferation, migration, and invasion of NPC cells. The molecular docking simulation assay confirmed that alisol A bound to YAP protein. In addition, alisol A promoted the phosphorylation of YAP and suppressed the expression of YAP in NPC cells. Alisol A inhibited the proliferation, migration, and invasion of NPC cells by inhibiting the Hippo signaling pathway. Alisol A may be a candidate drug for NPC.

Identifiants

pubmed: 34558868
pii: 62.895
doi: 10.3349/ymj.2021.62.10.895
pmc: PMC8470560
doi:

Substances chimiques

Cholestenones 0
alisol A 19885-10-0
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

895-902

Informations de copyright

© Copyright: Yonsei University College of Medicine 2021.

Déclaration de conflit d'intérêts

The authors have no potential conflicts of interest to disclose.

Références

Nat Rev Cancer. 2007 Mar;7(3):182-91
pubmed: 17318211
Trends Mol Med. 2015 Apr;21(4):212-22
pubmed: 25702974
Fitoterapia. 2012 Sep;83(6):1046-53
pubmed: 22613807
Biochimie. 2018 Sep;152:63-72
pubmed: 29959065
Am J Epidemiol. 2017 Jun 15;185(12):1272-1280
pubmed: 28459936
J Ethnopharmacol. 2014 Dec 2;158 Pt A:373-87
pubmed: 25446590
Oncol Res. 2020 Sep 1;28(4):371-383
pubmed: 32220262
J Nanosci Nanotechnol. 2019 Sep 1;19(9):5496-5502
pubmed: 30961702
Nat Genet. 2014 Aug;46(8):866-71
pubmed: 24952746
Ann N Y Acad Sci. 2017 Aug;1401(1):19-27
pubmed: 28891091
Bioorg Chem. 2019 Nov;92:103226
pubmed: 31491566
J Cancer. 2018 Jul 30;9(16):2852-2864
pubmed: 30123354
Acta Pharmacol Sin. 2017 Jan;38(1):69-79
pubmed: 27773935
Cell Cycle. 2008 Sep 1;7(17):2626-9
pubmed: 18758238
Cancer Med. 2016 Nov;5(11):3214-3222
pubmed: 27726305
J Vasc Res. 2016;53(5-6):291-300
pubmed: 27924795
Arch Toxicol. 2019 Nov;93(11):3367-3383
pubmed: 31563988
J BUON. 2007 Sep;12 Suppl 1:S101-18
pubmed: 17935268
BMC Cancer. 2019 May 22;19(1):482
pubmed: 31117967
Planta Med. 2006 Aug;72(10):951-4
pubmed: 16858666
Mol Med Rep. 2019 Aug;20(2):1187-1195
pubmed: 31173235
Anticancer Agents Med Chem. 2015;15(2):228-35
pubmed: 24893804
Chin J Cancer Res. 2019 Apr;31(2):375-388
pubmed: 31156308
Acta Biochim Biophys Sin (Shanghai). 2019 Nov 18;51(11):1096-1105
pubmed: 31696210
Cancer Metastasis Rev. 2017 Sep;36(3):435-447
pubmed: 28819752
PLoS One. 2013 Sep 06;8(9):e72927
pubmed: 24039823
Cell Mol Life Sci. 2018 Jul;75(13):2303-2319
pubmed: 29602952
Mol Cell Oncol. 2017 Feb 25;4(3):e1295127
pubmed: 28616573
Biomed Pharmacother. 2017 Mar;87:110-117
pubmed: 28049092
Exp Ther Med. 2019 Jun;17(6):4477-4484
pubmed: 31105786
Oncol Lett. 2019 Sep;18(3):2491-2499
pubmed: 31404330
J Clin Invest. 1999 Dec;104(12):1645-53
pubmed: 10606615
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Crit Rev Oncol Hematol. 2004 Mar;49(3):179-86
pubmed: 15036258
Molecules. 2019 Oct 10;24(20):
pubmed: 31658635
Phytomedicine. 2016 Jul 15;23(8):800-9
pubmed: 27288915
Arch Pharm Res. 2012 Nov;35(11):1919-26
pubmed: 23212633
Cancer Med. 2019 May;8(5):1958-1975
pubmed: 30945475

Auteurs

Xianghong Chen (X)

Department of Otolaryngology, Affiliated Hospital of Hebei University, Hebei, China.

Huiqing Liu (H)

Department of Otolaryngology, Affiliated Hospital of Hebei University, Hebei, China. sunyan2453@126.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH